These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 19853392)

  • 1. Degradation of N-hydroxy-3,4-methylenedioxymethamphetamine in aqueous solution and its prevention.
    Tsujikawa K; Kuwayama K; Miyaguchi H; Kanamori T; Iwata YT; Inoue H
    Forensic Sci Int; 2009 Dec; 193(1-3):106-11. PubMed ID: 19853392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary excretion profiles of N-hydroxy-3,4-methylenedioxymethamphetamine in rats.
    Tsujikawa K; Mikuma T; Kuwayama K; Miyaguchi H; Kanamori T; Iwata YT; Inoue H
    Xenobiotica; 2011 Jul; 41(7):578-84. PubMed ID: 21425955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of a new designer drug, N-hydroxy-3,4-methylenedioxymethamphetamine and its metabolites in rats using ultra-performance liquid chromatography-tandem mass spectrometry.
    Kikura-Hanajiri R; Kawamura M; Miyajima A; Sunouchi M; Goda Y
    Forensic Sci Int; 2010 May; 198(1-3):62-9. PubMed ID: 20299167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of MDMA and MDA in rat urine by semi-micro column HPLC-fluorescence detection with DBD-F and their monitoring after MDMA administration to rat.
    Wada M; Nakamura S; Tomita M; Nakashima MN; Nakashima K
    Luminescence; 2005; 20(3):210-5. PubMed ID: 15924321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High performance liquid chromatographic assays of the illicit designer drug "Ecstasy", a modified amphetamine, with applications to stability, partitioning and plasma protein binding.
    Garrett ER; Seyda K; Marroum P
    Acta Pharm Nord; 1991; 3(1):9-14. PubMed ID: 1677250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple and sensitive HPLC-fluorescence method for quantification of MDMA and MDA in blood with 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride (DIB-Cl) as a label.
    Tomita M; Nakashima MN; Wada M; Nakashima K
    Biomed Chromatogr; 2006 Dec; 20(12):1380-5. PubMed ID: 17080504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotoxicity mechanisms of thioether ecstasy metabolites.
    Capela JP; Macedo C; Branco PS; Ferreira LM; Lobo AM; Fernandes E; Remião F; Bastos ML; Dirnagl U; Meisel A; Carvalho F
    Neuroscience; 2007 Jun; 146(4):1743-57. PubMed ID: 17467183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
    McNamara R; Kerans A; O'Neill B; Harkin A
    Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical profiling of 3,4-methylenedioxymethamphetamine (MDMA) tablets seized in Hong Kong.
    Cheng WC; Poon NL; Chan MF
    J Forensic Sci; 2003 Nov; 48(6):1249-59. PubMed ID: 14640267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells.
    Jones DC; Lau SS; Monks TJ
    J Pharmacol Exp Ther; 2004 Oct; 311(1):298-306. PubMed ID: 15169827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA).
    Fonsart J; Menet MC; Debray M; Hirt D; Noble F; Scherrmann JM; Declèves X
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):339-47. PubMed ID: 19781562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sprague-Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
    Fonsart J; Menet MC; Declèves X; Galons H; Crété D; Debray M; Scherrmann JM; Noble F
    Toxicol Appl Pharmacol; 2008 Jul; 230(1):117-25. PubMed ID: 18358511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of acute psychotic episode after a single dose of ecstasy].
    Vaiva G; Bailly D; Boss V; Thomas P; Lestavel P; Goudemand M
    Encephale; 2001; 27(2):198-202. PubMed ID: 11407274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated adolescent 3,4-methylenedioxymethamphetamine (MDMA) exposure in rats attenuates the effects of a subsequent challenge with MDMA or a 5-hydroxytryptamine(1A) receptor agonist.
    Piper BJ; Vu HL; Safain MG; Oliver AJ; Meyer JS
    J Pharmacol Exp Ther; 2006 May; 317(2):838-49. PubMed ID: 16434566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection.
    Tomita M; Nakashima MN; Wada M; Nakashima K
    Biomed Chromatogr; 2007 Oct; 21(10):1016-22. PubMed ID: 17474141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-mortem redistribution of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in the rabbit. Part I: experimental approach after in vivo intravenous infusion.
    De Letter EA; Clauwaert KM; Belpaire FM; Lambert WE; Van Bocxlaer JF; Piette MH
    Int J Legal Med; 2002 Aug; 116(4):216-24. PubMed ID: 12185492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereochemical differences in the metabolism of 3,4-methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis.
    Cho AK; Hiramatsu M; Distefano EW; Chang AS; Jenden DJ
    Drug Metab Dispos; 1990; 18(5):686-91. PubMed ID: 1981721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy").
    Thompson MR; Callaghan PD; Hunt GE; Cornish JL; McGregor IS
    Neuroscience; 2007 May; 146(2):509-14. PubMed ID: 17383105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enantioselective determination of 3,4-methylene-dioxymethamphetamine and two of its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis.
    Lanz M; Brenneisen R; Thormann W
    Electrophoresis; 1997 Jun; 18(6):1035-43. PubMed ID: 9221895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of MDMA/MDA in both hair and urine in drug users.
    Han E; Yang W; Lee J; Park Y; Kim E; Lim M; Chung H
    Forensic Sci Int; 2005 Aug; 152(1):73-7. PubMed ID: 15939177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.